Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Gepubliceerd in:
1 Apotheekbereiding in de geneesmiddelenvoorziening hoofdstuk lezen eerste hoofdstuk lezen

2009 | OriginalPaper | Hoofdstuk

32 Oog

Auteurs : Adriaan van Sorge, Annick Ludwig

Gepubliceerd in: Recepteerkunde

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

De cornea (het hoornvlies) van het oog heeft weinig bloedvaatjes en daardoor kunnen wij zien. Maar dat is er tegelijkertijd de oorzaak van dat ooginfecties door het lichaam zelf moeilijk te bestrijden zijn en betrekkelijk snel kunnen leiden tot verlies van het oog. Een niet-beschadigd oog wordt zelden geïnfecteerd, omdat het cornea-epitheel een barrière vormt voor de meeste micro-organismen en de traanvloeistof antimicrobiële componenten bevat. De kans op infectie is veel groter als de cornea (zichtbaar of onzichtbaar) beschadigd is, bijvoorbeeld ten gevolge van een operatieve ingreep, contactlenzen of trauma.
vorige hoofdstuk 31 Oor
volgende hoofdstuk 33 Rectaal en vaginaal
Literatuur
1.
Broek PJ van den. Hindernissen overwinnen. Pharm Weekbl 2001;136:294–7.
2.
Visser LG, Meurs JC van, Swart W et al. Barrières omzeild, eliminatie ontweken. Pharm Weekbl 2001;136:299–303.
3.
SFK. Oogmedicatie onder de loep. Pharm Weekbl 2008;143:13–1.
4.
SFK. Niet door de mond. Pharm Weekbl 2009;144:1.
5.
Faure M. Les médicaments oculaires locaux des origines à nos jours. In Les préparations ophthalmiques. Ed. Ooteghem M van. Lavoisier TEC & amp; DOC, Paris 1995.
6.
Jansen JTG. Jood-povidon oogdruppels 0,03%. Pharm Weekbl 1982;117:42–0.
7.
van Sorge AA, Nispen tot Pannerden EBLM van et al. Oogdruppels met lage concentratie indometacine: bereidingsvoorschrift en onderzoek naar de werkzaamheid. Pharm Weekbl 1986;121:1039–46.
8.
Sivaprasad S, Bunce C, Wormald R. Non-steroidal anti-inflammatory agents for cystoid macular oedema following cataract surgery: a systematic review. Br J Ophthalmol 2005;89:1420–2.PubMed
9.
Sorge AA van, Wijnen PH, Delft JL van et al. Flurbiprofen, (S+), eyedrops: formulation, enantiomeric assay, shelf life and pharmacology. Pharm World Sci 1999;21:91–5.PubMed
10.
McLellan C, Ngo V, Pasedis S et al. Testing the long term stability of vancomycin ophthalmic solution. IJPC 2008;12:456–9.
11.
USP 31/NF 26. Cefazolin ophthalmic solution.
12.
Krämer I, Haber M, Pitz S, Pfeiffer N. Cefotaxim-lösung zur intraokularen Anwendung. Herstellung, Prüfung und Stabilität. Krankenhauspharmazie 1997;18:38–9.
13.
Protzko E, Bowman L, Abelson M et al. AzaSite clinical study Group. Phase 3 safety comparisons for 1.0% azithromycin in polymeric mucoadhesive eye drops versus 0,3% tobramycin eye drops for bacterial conjunctivitis. Invest Ophthalmol.Vis Sci 2007;48:3425–9.
14.
Kojima T, Higuchi A, Goto E et al. Autologous eye drops for the treatment of dry eye diseases. Cornea 2008;27:suppl 1: S25–30.PubMed
15.
Chiang C-C, Chen W-L, Lin J-M et al. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect. EYE 2009;23:290–3.PubMed
16.
Ceulemans J, Vermeire A, Adriaens E et al. Evaluation of a mucoadhesive tablet for ocular use. J Control Release 2001;77:333–44.PubMed
17.
Isenberg SJ, Apt L, Wood M. A controlled trial of povidone-iodine as prophylaxis against ophthalmia neonatorum. N Engl J Med 1995;332:562–6.PubMed
18.
Staatstoezicht op de Volksgezondheid. April 1980. Methode van Credé, ja of nee?
19.
Banker AS. Posterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome. Indian J Ophthalmol 2008;56:377–83.PubMed
20.
Biswas J, Sudharshan S. Anterior segment manifestations of human immnodeficiency virus/acquired immune deficiency syndrome. Indian J Ophthalmol 2008;56:363–75.PubMed
21.
Loftsson T, Sigurdsson HH, Konrádsdóttir F et al. Topical drug delivery to the posterior segment of the eye: anatomical and physiological considerations. Pharmazie 2008;63:171–9.PubMed
22.
Avtar R, Tandon D. Modeling the drug transport in the anterior segment of the eye. Eur J Pharm Sci 2008;35:175–82.PubMed
23.
Lee T W-Y, Robinson JR. Drug delivery to the posterior segment of the eye IV: theoretical formulation of a drug delivery system for subconjunctival injection. J Ocular Pharmacol Ther 2009;25:29–37.
24.
Editorial. Diabetes and Obesity. A challenge for every ophthalmologist. Arch Ophthalmol 2009;127:328–9.
25.
Nagpal M, Nagpal K, Nagpal PN. A comparative debate on the various anti-vascular endothelial growth factor drugs: pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin). Indian J Ophthalmol 2007;55:437–9.PubMed
26.
Urtti A. Challenges and obstacles of ocular pharmacokinetics and drug delivery. Adv Drug Deliv Rev 2006;58:1131–5.PubMed
27.
Shirasaki Y. Molecular design for enhancement of ocular penetration. J Pharm Sci 2008;97:2462–96.PubMed
28.
del Amo EM, Urtti A. Current and future ophthalmic drug delivery systems. A shift to the posterior segment. Drug Deliv Today 2008;13:135–43.
29.
Çekiç O, Batman C, Yasar Ü et al. Comparison of subretinal fluid levels of two 0,3% ciprofloxacin-containing eye drops. Clin Exp Ophthalmol 2001;29:30–2.
30.
Sigurdsson HH, Konrádsdóttir F, Loftsson T et al. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. Acta Ophthalmol Scand 2007;85:598–602.PubMed
31.
Riegelman S, Vaughan DG, Okumoto M. Compounding ophthalmic solutions. Suggestions for a safe, practical approach. J Am Pharm Ass 1955;16:742–6.
32.
Riegelman S, Vaughan DG. A rational basis for the preparation of ophthalmic solutions. Current review. Surv Ophthalmol 1958;3:471–92.PubMed
33.
34.
American Society of Hospital Pharmacists. ASHP technical assistance bulletin on pharmacy-prepared ophthalmic products. Am J Hosp Pharm 1993;50:1462–3.
35.
McClellan KA. Mucosal defense of the outer eye. Surv Ophthalmol 1997;42:233–46.PubMed
36.
Chandler JW. Gillette TE. Immunologic defense mechanisms of the ocular surface. Ophthalmology 1983;90:585–91.PubMed
37.
Friedenwald JS, Hughes jr WF, Herrmann H. Acid-base tolerance of the cornea. Arch Opthalmol 1944;31:279–83.
38.
Gonnering R, Edelhauser HF, van Horn DL et al. The pH tolerance of rabbit and human corneal endothelium. Invest Ophthalmol Vis Sci 1979;18:373–90.PubMed
39.
Stern ME, Gao J, Siemasko KF, Beuerman RW, Pflugfelder SC. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res 2004;78:409–16.PubMed
40.
Argüeso P, Gipson IK. Epithelial mucins of the ocular surface: structure, biosynthesis and function. Exp Eye Res 2001;73:281–9.PubMed
41.
Stein R, Hurwitz JJ. Anatomy and physiology of tear secretion. Hoofdstuk 1: 1-8. In: The Lacrimal System. JJ Hurwitz. Lippincott-Raven. Philadelphia, New York. ISBN 0-7817-0334-4. 1995.
42.
Forrester JV. Privilege revisited: an evaluation of the eye's defence mechanisms. EYE 2009;23:756–66.PubMed
43.
Meek B, Speijer D, Jong PTVM de et al. The ocular humoral response in health and disease. Prog Retin Eye Res 2003;22:391–415.PubMed
44.
Huang LC, Jean D, Proske RJ et al. Ocular surface expression and in vitro activity of antimicrobial peptides. Curr Eye Res 2007;32:595–609.PubMedCentralPubMed
45.
Huang LC, Redfern RL, Narayanan S et al. In vitro activity of human B-defensin 2 against Pseudomonas aeruginosa in the presence of tear fluid. Antimicrob Agents Chemother 2007;51:3853–60.PubMed
46.
Redl B. Human tear lipocalin. Biochim Biophys Acta 2000;1482:241–8.PubMed
47.
Gasymov OK, Abduragimov AR, Prasher P et al. Tear lipocalin: evidence for a scavenging function to remove lipids from the human corneal surface. Invest Ophthalmol Vis Sci 2005;46:3589–96.PubMed
48.
Caffery B, Joyce E, Boone A et al. Tear lipocalin and lysozyme in Sjögren and non-Sjögren dry eye. Optom Vis Sci 2008;85:661–7.PubMed
49.
50.
Ludwig A, Ootegem M van. The study of the precorneal dynamics of ophthalmic solutions by fluorometry. Pharm Acta Helv 1986;85:59–65.
51.
Tiffany JM, Winter N, Bliss G. Tear film stability and tear surface tension. Curr Eye Res 1989;8:507–15.PubMed
52.
Ousler III GW, Hagberg KW, Schindelar M et al. The ocular protection index. Cornea 2008;27:509–13.
53.
Ousler GW III, Michaelson C, Christensen MT. An evaluation of tear film breakup time extension and ocular protection index scores among three marketed lubricant eye drops. Cornea 2007;26:949–52.PubMed
54.
Report of the International Dry Eye Workshop (DEWS) April 2007;5:2. Special issue of The Ocular Surface; www.theocularsurface.com.
55.
Rolando M, Autori S, Baino F et al. Protecting the ocular surface and improving the quality of life of drye eye patients: a study of the efficacy of an HP-Guar containing ocular lubricant in a population of dry eye patients. J Ocular Pharmacol Ther 2009;25:1–7.
56.
Durrani AM, Farr SJ, Kellaway IW. Influence of molecular weight and formulation pH on the precorneal clearance rate of hyaluronic acid in the rabbit eye. Int J Pharmaceutics 1995;118:243–50.
57.
Troiano P, Monaco G. Effect of hypotonic 0,4% hyaluronic acid drops in dry eye patients: a cross-over study. Cornea 2008;27:1126–30.PubMed
58.
Guthoff RF, Wienss H, Hahnel C et al. Epithelial innervation of human cornea. A three-dimensional study using confocal laser scanning fluorescence microscopy. Cornea 2005;24:608–13.PubMed
59.
Belmonte C, Acosta MC, Gallar J. Neural basis of sensation in intact and injured corneas. Exp Eye Res 2004;78:513–25.PubMed
60.
Acosta MC, Alfaro ML, Borrás F et al. Influence of age, gender and iris color on mechanical and chemical sensitivity of the cornea and conjunctiva. Exp Eye Res 2006;83:932–8.PubMed
61.
Polak BCP, Henkes HE. Bijwerkingen van geneesmiddelen in de oogheelkunde. Ned Tijdschr Geneeskd 1987;131:2254–7.PubMed
62.
Ghate D, Edelhauser HF. Barriers to glaucoma drug delivery. J Glaucoma 2008;17:147–56.PubMed
63.
Longwell A, Birss S, Keller N et al. Effect of topically applied pilocarpine on tear film pH. J Pharm Sci 1976;65:1654–7.PubMed
64.
Wang ESN, Hammarlund ER. Corneal absorption reinforcement of certain mydriatics. J Pharm Sci 1970;59:1559–63.PubMed
65.
Grass GM, Robinson JR. Mechanisms of corneal drug penetration I: in vivo and in vitro kinetics. J Pharm Sci 1988;77:3–14.PubMed
66.
Grass GM, Robinson JR. Mechanisms of corneal drug penetration II: Ultrastructural analysis of potential pathways for drug movement. J Pharm Sci 1988;77:15–23.PubMed
67.
Grass GM, Robinson JR. Mechanisms of corneal drug penetration III: Modeling of molecular transport. J Pharm Sci 1988;77:24–6.PubMed
68.
Keister JC, Cooper ER, Missel PJ et al. Limits on ocular drug delivery. J Pharm Sci 1991;80:50–3.PubMed
69.
Keister JC, Heidmann PS, Missel PJ. Transient analysis of ocular drug delivery: zero-volume effect. J Pharm Sci 1997;86:1040–5.PubMed
70.
Rojanasakul Y, Robinson JR. Transport mechanisms of the cornea: characterization of barrier permselectivity. Int J Pharm 1989;55:237–46.
71.
Gupta M, Majumdar DK. Effect of concentration, pH, and preservative on in vitro transcorneal pemeation of ibuprofen and flurbiprofen from non-buffered aqueous drops. Indian J Exp Biol 1997;35:844–9.PubMed
72.
Malhotra M, Majumdar DK. Permeation through cornea. Indian J Exp Biol 2001;39:11–24.PubMed
73.
Fuchsjäger-Mayrl G, Zehetmayer M, Plass H et al. Turnheim K. Alkalinization increases penetration of lidocaine across the human cornea. J Cataract Refract Surg 2002;28:692–6.PubMed
74.
Santvliet van L, Ludwig A. Determinants of eye drop size. Surv Ophthalmol 2004;49:197–213.PubMed
75.
Lederer CM, Harold ME. Drop size of commercial glaucoma medications. Am J Ophthalmol 1986;101:691–4.PubMed
76.
Sorensen SJ, Abel SR. Drop size of ocular carteolol hydrochloride. Am J Hosp Pharm 1994;51:1470–3.
77.
Mitrovic D. Enquete in Nederland november 2008.
78.
Davies NM. Biopharmaceutical considerations in topical ocular drug delivery. Clin Exp Pharmacol Physiol 2000;27:558–62.PubMed
79.
Conrad JM, Reay WA, Polcyn RE et al. Influence of tonicity and pH on lacrimation and ocular drug bioavailability. J Parenter Drug Assoc 1978;32:149–61.PubMed
80.
Ludwig A, van Ooteghem M. The influence of the osmolality on the precorneal retention of ophthalmic solutions. J Pharm Belg 1987;42:259–66.PubMed
81.
Chrai SS, Patton TF, Mehta A et al. Lacrimal and instilled fluid dynamics in rabbit eyes. J Pharm Sci 1973;62:1112–21.PubMed
82.
Richard D, Clanet C, Quéré D. Contact time of a bouncing drop. Nature 2002;417:81–1.
83.
Sullivan DA (red.). 1994. Lacrimal gland, Tear film, and Dry Eye Syndromes. Farris RL. Tear osmolarity - a new gold standard? 495–503.
84.
Boers GW, van de Rijt SMHEM, van Asten P. Oogdruppels: (bij)werking, concentratie en toedieningsfrequentie. Pharm Weekbl 1993;128:144–1.
85.
Ellis PP, Wu P-Y, Pfoff DS et al. Effect of nasolacrimal occlusion on timolol concentrations in the aqueous humor of the human eye. J Pharm Sci 1992;81:219–20.PubMed
86.
Chrai SS, Makoid MC, Eriksen SP et al. Drop size and initial dosing frequency problems of topically applied drugs. J Pharm Sci 1974;63:333–8.PubMed
87.
Anderson JA, Chen CC. Multiple dosing increases the ocular bioavailability of topically administered flurbiprofen. Arch Ophthalmol 1988;106:1107–9.PubMed
88.
Coles WH, Jaros PA. Dynamics of ocular surface pH. Br J Ophthalmol 1984;68:549–52.PubMed
89.
Trolle-Larsen C. Investigations into the sensitivity of the human eye to hypo- and hypertonic solutions as well as solutions with unphysiological hydrogen ion concentrations. Pharm Weekbl 1959;93:148–55.
90.
Frauch P. Tränendrüsensekrete und präkornealer film beim gesunden Menschen. Pharm Acta Helv 1978;53:1–16.PubMed
91.
Carney LG, Mauger TF, Hill RM. Buffering in human tears: pH responses to acid and base challenge. Invest Ophthalmol Vis Sci 1989;30:747–54.PubMed
92.
Irritatie bij pilocarpineoogdruppels. Pharm Weekbl 2000;135:3–1.
93.
Pitz S, Haber M, Pfeiffer N. Beobachtungen über den pH-Wert verschiedener Tränenersatzmittel. Klin Monatsbl Augenheilkd 1998;213:123–4.PubMed
94.
Ophthalmic preparations. Part 5: pharmaceutical manufacturing, in: 2005 Troy DB (Ed.) Remington: The science and practice of pharmacy 21 Ed. Lippincott, Williams & amp; Wilkins:862.
95.
Riegelman S, Vaughan jr DG, Okumoto M. Compounding ophthalmic solutions. J Am Pharm Assn 1955;16:742–6.
96.
Gilbard JP, Rossi SR, Heyda KG. Ophthalmic solutions, the ocular surface, and a unique therapeutic artificial tear solution. Am J Ophthalmol 1989;107:348–55.PubMed
97.
Draize JH, Woodward G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377–90.
98.
Nadal J, Fuente V de la, Aradias M et al. Toxic coma induced by anticholinergic eye drops. Br Med J. 1987;295:135–2.
99.
Nieminen T, Lehtimäki T, Mäenpää J et al. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest 2007;67:237–45.
100.
Polak BCP, Völker-Dieben HJM. Oogdruppels soms levensgevaarlijk. Medisch Contact 2000;55:248–51.
101.
Adler AG, McElwain GE, Merli GJ et al. Systemic effects of eye drops. Arch Intern Med 1982;142:2293–4.PubMed
102.
Klootwijk APJ, Roelandt JRTC. Systemische bijwerkingen van oogdruppels: een onopvallende oorzaak van hartritmestoornissen. Ned Tijdschr Cardiol 1992;6:145–8.
103.
Begeman CJ, Peels CH, Verheugt FWA. Bijna dood door een mydriaticum. Hart Bulletin 1988;19:96–7.
104.
Chamberlain TJ. Myocardial infarction after ophthalmic betaxolol. N Engl J Med 1989;321:134–2.
105.
Pringle SD, MacEwen CJ. Severe bradycardia due to interaction of timolol eye drops and verapamil. Br Med J 1987;294:155–6.
106.
Polak BCP, Völker-Dieben HJM. De fatale druppel. Pharm Weekbl 2001;136:317–20.
107.
Polak BCP. Eén druppel soms nog te veel. Pharm Weekbl 2002;137:358–62.
108.
Passier-Heeremans JLM, Boer Y. Aanbevelingen voor een veiliger gebruik van chlooramfenicol in de oogheelkunde. Pharm Weekbl 1997;132:1410–3.
109.
Codex der Augenarzneistoffe und Hilfsstoffe in: Dolder, R. & amp; Skinner, FS. 1990. Ophthalmika: Pharmakologie, Biopharmazie und Galenik der Augenarzneimittel. 4e Auflage. Stuttgart: Wissenschaftliche Verlagsgesellschaft.
110.
Dreijer-Van der Glas SM, Bult A. Incompatibility of indometacin and benzalkonium in eye drops due to ion-pair formation. Pharm Weekbl Sci Ed 1987;9:29–32.
111.
Product information Miglyol®, neutral oils for pharmaceuticals and cosmetics. Via: http://​abstracts.​aapspharmaceutic​a.​com.​
112.
Horikx A. WINAp. Boorzuur in oogdruppels ook beneden 3 jaar. Pharm Weekbl 2005;140:18–2.
113.
Proosdij-Hartzema EG van. Boriumverbindingen. Verleden heden en toekomst. Ned Tijdschr Geneesk 1966;110:2260–9.
114.
Schuller WO, Young WH, Hill RM. Clinical measurement of the tears: viscosity. J Am Optom Assoc. 1972;43:1358–61.
115.
Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliv Rev 2005;57:1595–1639.PubMed
116.
Weyenberg W, Ludwig A. In vitro assessment of the interaction mechanisms between mucin and a cationic cellulose derivative by rheological methods using an experimental design. Pharmazie 2002;57:628–31.PubMed
117.
Santvliet L van, Ludwig A. Influence of the physico-chemical properties of ophthalmic viscolysers on the weight of drops dispensed from a flexible dropper bottle. Eur J Pharm Sci 1999;7:339–345.
118.
Santvliet L van, Ludwig A. Biopharmaceutical, technological and pharmaceutical care aspects of eye-drops. Farm Tijdschrift België 2000;2:14–27.
119.
Santvliet L van, Ceulemans J, Koppen C et al. Physicochemical aspects of artificial tear formulations. Farm Tijdschrift België 2000;3:16–23.
120.
Tiffany JM, Winter N, Bliss G. Tear film stability and tear surface tension. Curr Eye Res 1989;8:507–15.PubMed
121.
Tromp THFJ, Dankert J, De Rooy S et al. De conservering van oogdruppels III. Een onderzoek naar de interactie van hydroxypropylmethylcellulose en benzalkoniumchloride. Pharm Weekbl 1976;111:561–9.
122.
Greaves JL, Wilson CV. Treatment of diseases of the eye with mucoadhesive delivery systems. Adv Drug Deliv Rev 1993;11:349–83.
123.
Zigani M, Tabatabay C, Gurny R. Topical semi-solid drug delivery: kinetics and tolerance of ophthalmic hydrogels. Adv Drug Deliv Rev 1995;16:51–60.
124.
Karmarkar AB. Poloxamers and their applications. Via: www.pharmainfo.net/pharma-student-magazine/poloxamers-and-their-applications. Geraadpleegd juli 2008.
125.
Jiao J. Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. Adv Drug Deliv Rev 2008;60:1663–73.PubMed
126.
Bullock JD. Temperature instability of ReNu with MoistureLoc. A new theory to explain the worldwide Fusarium keratitis epidemic of 2004-2006. Arch Ophthalmol 2008;126:1493–8.PubMed
127.
Behlau I, Gilmore MS. Microbial biofilms in ophthalmology and infectious disease. Arch Ophthalmol 2008;126:1572–81.PubMed
128.
Editorial. What makes microbes stick? Lancet 1988;II:1343–4.
129.
Liu Y, Pinzon-Arango PA, Strauss J et al. Fundamentals of bacterial adhesion applied toward infection prevention: focus on two case studies. Pharm Engineering 2009;29:56–66.
130.
Jaenen N, Baudouin C, Pouliquen P et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007;17:1–6.
131.
Furrer P, Mayer JM, Gurny R. Ocular tolerance of preservatives and alternatives. Eur J Pharm Biopharm 2002;53:263–80.PubMed
132.
Madhu C, Rix PJ, Shackleton MJ et al. Effect of benzalkonium chloride/EDTA on the ocular bioavailability of ketorolac tromethamine following ocular instillation to normal and de-epithelialized corneas of rabbits. J Pharm Sci 1996;85:415–8.PubMed
133.
Kikuchi T, Suzuki M, Kusai A et al. Synergistic effect of EDTA and boric acid on corneal penetration of CS-088. Int J Pharm 2005;290:83–9.PubMed
134.
Matthews BR, Skinner FS. Aspects of the preservative requirements for multiple dose eye care products. Eur J Parenteral Pharm Sci 2006;11:23–8.
135.
Boer Y. Irritation by eye drops containing 2-phenylethanol. Pharm Weekbl Sci Ed 1981;3:122–3.
136.
Tan M, Parkin JE. Route of decomposition of thiomersal (thimerosal). Int J Pharm 2000;208:23–34.PubMed
137.
Veen AJ van ‘t, Joost Th van. Bron en praktische betekenis van allergie voor thiomersal, een organische kwikverbinding. Ned Tijdschr Geneeskd 1996;140:297–300.
138.
Winder AF, Sheraidah GAK, Astbury NJ et al. Penetration of mercury from ophthalmic preservatives into the human eye. Lancet 1980;2:237–9.PubMed
139.
Richardson NE, Davies DJG, Meakin BJ et al. Containers, preservatives and contact lens solutions. Pharm J 1979;223:462–4.
140.
Boer Y, Nijland CJ. Conserveermiddelen en oogdruppelverpakking. Pharm Weekbl 1981;116:371–4.
141.
Boer Y, Nijland CJ. Sorptie van conserveermiddelen door membraanfilters bij de bereiding van oogdruppels. Pharm Weekbl 1981;116:374–6.
142.
Spingler E. Inkompatibilitäten bedingt durch Behältermaterial. Schweiz Apoth Ztg 1974;112:66–1.
143.
Horssen N van. Oogdruppels zonder conserveermiddel. Pharm Weekbl 1990;125:1344–6.
144.
Dutot M, Paillet H, Chaumeil C et al. Severe ocular infections with contact lens: role of multipurpose solutions. EYE 2009;23:470–6.PubMed
145.
Ceylan Y. Risico op contaminatie is hoog. 94% van de glaucoompatiënten druppelt verkeerd. Pharm Weekbl 2005;112:1054–5.
146.
Åslund B, Olson OT, Sandell E. Studies on in-use microbial contamination of eye drops. Acta Pharm Suec. 1978;15:389–94.PubMed
147.
Waylward GW, Wilson RS. Contamination of dropper bottles with tear fluid in an ophthalmic outpatient clinic. Br Med J 1987;294:158–7.
148.
Stevens JD, Matheson MM. Survey of the contamination of eydrops of hospital inpatients and recommendations for the changing of current practice in eyedrop dispensing. Br J Ophthalmol 1992;76:36–8.PubMed
149.
Recommendations for preventing possible HTLV-III/LAV virus from tears. JAMA 1985;254:142–9.
150.
Krishnan T, Sengupta S, Reddy PR et al. Secondary pseudomonas infection of fungal keratitis following use of contaminated natamycin eye drops: a case series. EYE 2009;23:477–9.PubMed
151.
Panday PVN, Heiden J van der, Dillingh J et al. Microbiologische validatie van de oogdruppelflacon met snap-cap: de casus acetylcysteïneoogdruppels 5%. Pharm Weekbl Wetenschappelijk Platform 2007;1:16–21.
152.
Rihawi S, Frentz M, Schrage NF. Emergency treatment of eye burns: which rinsing solution should we choose? Graefe's Arch Clin Exp Ophthalmol 2006;244:845–54.
153.
Rihawi S, Frentz M, Becker J et al. The consequences of delayed intervention when treating chemical eye burns. Graefe's Arch Clin Exp Ophthalmol 2007;245:1507–13.
154.
Bouvy M. Chlooramfenicol lijkt veilig in oogdruppels en oogzalf. Pharm Weekbl 1998;133:853–4.
155.
Lancaster T, Swart AM, Jick H. Risk of serious haematological toxicity with use of chloramphenicol eye drops in a British general practice database. Br Med J 1998;316:66–7.
156.
Wiholm B-E, Parsells Kelly J, Kaufman D et al. Relation of aplastic anaemia to use of chloramphenicol eye drops in two international case-control studies. Br Med J 1998;316:66–6.
157.
Doona M, Walsh JB. Topical chloramphenicol is an outdated treatment. Br Med J 1998;316:190–3.
158.
Doona M, Walsh JB. Use of chloramphenicol as topical eye medication: time to cry halt? Br Med J 1995;310:1217–8.
159.
LNA. Basisoplossingen oogdruppels opnieuw verwarmen? Pharm Weekbl 1993;128:60–9.
160.
Brouwers JRBJ. Erytromycine-oogzalf, bereiding en analyse. Pharm Weekbl 1984;119:1076–7.
161.
Wagenaar R. Tetracycline oogzalf: conflicterende eisen. Pharm Weekbl 2006;141:95–6.
162.
Romijn M. Een betere oplossing. Tetracycline oogzalf: conflicterende eisen. Pharm Weekbl 2006;141:101–9.
163.
Dua HS. Bacterial keratitis in the critically ill and comatose patient. Lancet 1998;351:387–8.PubMed
164.
Klein Haneveld J. Dikker hoornvlies bemoeilijkt behandeling glaucoom. Pharm Weekbl 2005;140:140–1.
165.
Dreyer EB. Too thick for your drugs. Am J Opthalmol 2004;138:847–8.
166.
Kass MA et al. for the Ocular Hypertension Treatment Study Group. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701–13.
167.
Bouvy M, Vellasamy-Posthumus H, Sterk CC. Glaucoommedicatie in 1998 en 1999. Pharm Weekbl 2001;136:311–5.
168.
Smet PAGM de, van Drooge MJ. Hoe glaucoompatiënten oogdruppels gebruiken. Potentiële betekenis van toedieningsproblemen. Pharm Weekbl 2000;135:1096–9.
169.
Drooge MJ van, de Smet PAGM. Hoe glaucoompatiënten oogdruppels gebruiken. Instructieprotocol onderzocht in proefproject. Pharm Weekbl 2000;135:1016–20.
170.
Kholdebarin R, Campbell RJ, Jin Y-P et al. (Canadian Compliance study group). Multicenter study of compliance and drop administration in glaucoma. Can J Ophthalmol 2008;43:454–61.PubMed
171.
Rahim SA, Sahlas DJ, Shadowitz S. Blinded by pressure and pain. Lancet 2005;365:224–4.
172.
Bisterveld JHGM. De behandeling van glaucoom. Pharm Weekbl 2001;136:305–9.
173.
Lacey J, Cate H, Broadway DC. Barriers to adherence with glaucoma medications: a research study. EYE 2009;23:924–32.PubMed
174.
Santvliet L van, Ludwig A. Influence of the dropper tip design on the size of eye-drops. Pharm Ind 2001;63:402–9.
175.
Santvliet L van, Ludwig A. Dispensing eye drops from flexible plastic dropper bottles. Part I: Influence of the packaging characteristics. Pharm Ind. 1999;61:92–6.
176.
Santvliet L van, Ludwig A. Dispensing eye drops from flexible plastic dropper bottles. Part II: Influence of the physico-chemical properties of the formulation and the manipulation technique by the patient. Pharm Ind 1999;61:194–8.
177.
Santvliet L van, Ludwig A. Dispensing eye drops from flexible plastic dropper bottles. Part III: Comparison between volunteers and elderly patients. Pharm Ind 1999;61:276–80.
178.
Gebhardt DOE. Druppeltechniek s.v.p. standaardiseren. Pharm Weekbl 2001;136:108–2.
179.
WINAp. Handige instructies op apotheek.nl. Pharm Weekbl 2009;144:2–3.
180.
181.
182.
Fraunfelder FT. Extraocular fluid dynamics: how best to apply topical ocular medication. Trans Am Ophthalmol Soc 1976;74:457–87.PubMed
183.
Croonen H. Ook de oogdruppels gaan moeilijk. Pharm Weekbl 2005;140:54–5.
184.
Burns E, Mulley GP. Practical problems with eye-drops among elderly ophthamology outpatients. Age Ageing 1992;21:168–70.PubMed
185.
Smith SE. Eyedrop instilllation for reluctant children. Br J Ophthalmol 1991;75:480–1.PubMed
186.
WINAp. Patiënt kan niet zonder productzorg. Pharm Weekbl 2008;143:4–1.
187.
Buhrs E. Nog veel te veel gepeuter... Pharm Weekbl 2008;143:36–7.
Metagegevens
Titel
32 Oog
Auteurs
Adriaan van Sorge
Annick Ludwig
Copyright
2009
Uitgeverij
Bohn Stafleu van Loghum
Boek
Recepteerkunde

Print ISBN: 978-90-313-5316-3

Elektronisch ISBN: 978-90-313-8032-9

Copyright: 2009

DOI
https://doi.org/10.1007/978-90-313-8032-9_32